Clinical trials: Extrapulmonary Tuberculosis, open to volunteers
Tuberculosis Meningitis
Phase 2a Trial of Alpibectir Plus Ethionamide for Tuberculosis Meningitis
AlpE is a novel drug combination under development for the treatment of TB, with several positive attributes for TBM, including rapid bactericidal activity.
- Trial name
- NCT07350174
- Testing
- HRZE, HRZE plus Alpe375, HRZE plus AlpE500
- Volunteers
- 64 people
- Sponsor
- BioVersys AG
Tuberculosis, Pleural, Pleural Biopsy
Diagnostic Utility of Mycobacterium Tuberculosis Cell-free DNA in Hong Kong
Tuberculosis (TB) is an endemic infectious disease in Hong Kong and a global health threat. Tuberculous pleuritis (TBP) is the most common form of extrapulmonary tuberculosis in China.
- Trial name
- MYDNITE-3 (NCT06646237)
- Where
- Hong Kong
- Volunteers
- 350 people
- Sponsor
- Chinese University of Hong Kong
Tuberculosis, Meningeal, Tuberculosis; Meningitis (Etiology)
Adjunctive Doxycycline for Central Nervous System Tuberculosis
Although tuberculosis is now considered a treatable disease, central nervous system tuberculosis (CNS-TB) when managed with the current standard-of-care (SOC), still has mortality rates ranging from 30-50% even in tertiary…
- Conditions
- Tuberculosis, Meningeal, Tuberculosis; Meningitis (Etiology), Tuberculosis, Central Nervous System, Tuberculosis; Meningoencephalitis (Etiology)
- Trial name
- DIRECT (NCT06446245)
- Testing
- Doxycycline, Anti Tuberculosis Drug, Adjunctive corticosteroid
- Where
- 6 sites in Indonesia, Malaysia and 1 more
- Volunteers
- 200 people
- Sponsor
- National University Hospital, Singapore
Tuberculosis
Tuberculosis Clinical Registry in Europe
The TBnet registry is a multinational, prospective tuberculosis registry established by the Tuberculosis Network European Trialsgroup (TBnet e.V.) to collect and analyze long-term data from TB patients across Europe.
- Trial name
- NCT07677904
- Testing
- data collection
- Where
- 2 sites in Germany, Italy
- Volunteers
- 1,000 people
- Sponsor
- Research Center Borstel
Tuberculosis, Spinal, Tuberculosis, Osteoarticular
Gene Expression Profiles in Spinal Tuberculosis.
Tuberculosis (TB) is one of the top ten causes of death worldwide with approximately 10 million cases globally and 1.2 million deaths. Sub-Saharan Africa carries the highest burden of TB.
- Conditions
- Tuberculosis, Spinal, Tuberculosis, Osteoarticular, Tuberculosis, Mycobacterium Infections
- Trial name
- SpinalTBX (NCT05610098)
- Where
- South Africa
- Volunteers
- 100 people
- Sponsor
- University of Cape Town
Tuberculosis, Pleural
Diagnostic Utility of Mycobacterium Tuberculosis Cell-free DNA
Tuberculosis (TB) is one of the major global health threats and is the second leading infectious cause of death after COVID-19 in 2022.
- Trial name
- MYDNITE-2 (NCT06439810)
- Testing
- Mycobacterium tuberculosis (MTB) cell-free DNA (cfDNA)
- Where
- Hong Kong
- Volunteers
- 400 people
- Sponsor
- Chinese University of Hong Kong
Tuberculosis, Extrapulmonary Tuberculosis
Biomarker Analysis for Diagnosing and Treatment Monitoring in Extrapulmonary Tuberculosis Patients in Nairobi, Kenya
Tuberculosis (TB) remains a global health threat with high incidence, especially in Africa. The proportion of extrapulmonary TB (EPTB) can escalate up to 36% in areas with a high HIV prevalence.
- Conditions
- Tuberculosis, Extrapulmonary Tuberculosis, Mycobacterium Tuberculosis
- Trial name
- BioTube (NCT07901387)
- Where
- 2 sites in Kenya
- Volunteers
- 700 people
- Sponsor
- Nagasaki University
Tuberculosis, Meningitis
Phase II Clinical Study of Contezolid for the Treatment of Tuberculous Meningitis
Contezolid is a novel oxazolidinone antibiotic developed by Shanghai Mengke Pharmaceutical Co., Ltd., which successfully went public in 2021.
- Trial name
- NCT06811025
- Testing
- Contezolid, Linezolid (LZD)
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Beijing Chest Hospital
Pulmonary and Extra- Pulmonary Tuberculosis (TB)
Study About Drug Resistance of Mycobacterium Tuberculosis
Tuberculosis is a major cause of ill health and one of the leading causes of death worldwide. Early, rapid and accurate diagnosis of all TB patients and prompt treatment with any form of drug-susceptible or drug resistant TB is…
- Trial name
- NCT07169149
- Where
- Egypt
- Volunteers
- 250 people
- Sponsor
- Sohag University
Mycobacterium Tuberculosis, Tuberculosis, Pulmonary
Blood Tuberculosis DNA Levels to Monitor Tuberculosis Treatment
Tuberculosis (TB) is a leading infectious cause of death worldwide. Current strategies for monitoring TB treatment response are culture dependent and insensitive.
- Conditions
- Mycobacterium Tuberculosis, Tuberculosis, Pulmonary, Tuberculosis, Extra-Pulmonary
- Trial name
- Mtb-Dynamic (NCT06845618)
- Where
- Thailand
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Extrapulmonary Tuberculosis
MBLA to Differentiate IRIS From Treatment Failure in Extrapulmonary Tuberculosis
This prospective, multi-center study aims to evaluate the Molecular Bacterial Load Assay (MBLA) on lymph node aspirates as a tool to distinguish between late immune reconstitution inflammatory syndrome (IRIS) and treatment…
- Trial name
- MBLA_IRIS (NCT07778082)
- Testing
- MBLA from routine lymph node aspirate
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Research Center Borstel
Tuberculous Meningitis, HIV
BPaLMZ for TB Meningitis
This two-stage study will compare consented research participants with tuberculous meningitis receiving experimental Bedaquiline (B), Pretomanid (Pa), Linezolid (L); Moxifloxacin (M), Pyrazinamide (Z) known as (BPaLMZ) to…
- Conditions
- Tuberculous Meningitis, HIV, Meningitis, TB - Tuberculosis
- Trial name
- BPaLMZ (NCT07227779)
- Testing
- BPaLMZ Regimen
- Where
- 2 sites in Uganda
- Volunteers
- 312 people
- Sponsor
- David Boulware
Tuberculosis, Tuberculosis, Pulmonary
Shortened Regimen for Drug-susceptible TB in Children
While drug-susceptible tuberculosis (TB) disease in children currently requires four to six months of treatment, most children may be able to be cured with a shorter treatment of more powerful drugs.
- Conditions
- Tuberculosis, Tuberculosis, Pulmonary, Tuberculosis, Lymph Node, Mycobacterium Tuberculosis
- Trial name
- SMILE-TB (NCT06253715)
- Testing
- Isoniazid, Rifampin, Pyrazinamide
- Where
- 9 sites in India, Indonesia and 5 more
- Volunteers
- 860 people
- Sponsor
- Johns Hopkins University
Tuberculous Meningitis
Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis
The purpose of this study is to compare a 6-month regimen of high-dose rifampicin (RIF), high-dose isoniazid (INH), linezolid (LZD), and pyrazinamide (PZA) versus the World Health Organization (WHO) standard of care (SOC)…
- Trial name
- NCT05383742
- Testing
- Rifampicin (RIF), Isoniazid (INH), Linezolid (LZD)
- Where
- 18 sites in Brazil, India and 10 more
- Volunteers
- 330 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculous Meningitis
Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis
INTENSE-TBM is randomized controlled, phase III, multicenter, 2 x 2 factorial plan superiority trial assessing the efficacity of two interventions to reduce mortality from tuberculous meningitis (TBM) in adolescents and adults…
- Trial name
- INTENSE-TBM (NCT04145258)
- Testing
- Aspirin, WHO TBM treatment, Intensified TBM treatment
- Where
- 13 sites in Côte d’Ivoire, Madagascar and 2 more
- Volunteers
- 768 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Tuberculous Meningitis
Intensified Short Course Regimen for TBM in Adults
Tuberculous meningitis (TBM) is the most lethal form of extra pulmonary tuberculosis. This devastating disease kills almost a third of its sufferers and disables a significant proportion of the survivors.
- Trial name
- INSHORT (NCT05917340)
- Testing
- High dose rifampicin (25mg/kg), Moxifloxacin 400mg, Aspirin 150 mg
- Where
- India
- Volunteers
- 372 people
- Sponsor
- Indian Council of Medical Research
Tuberculous Meningitis, HIV I Infection
Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis
Randomized phase II clinical trial which aims to assess the impact on 3-month mortality and safety of adding adalimumab to standard treatment (anti-tuberculosis drugs and corticosteroids) in HIV patients with tuberculosis…
- Trial name
- TIMPANI (NCT05590455)
- Testing
- Adalimumab Injection
- Where
- 3 sites in Brazil, Mozambique and 1 more
- Volunteers
- 130 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Extrapulmonary Tuberculosis
A Multicentric Cohort and Biomarker Study for Improved Care of Patients with Extrapulmonary Tuberculosis
This is a prospective, multicenter, observational study (mEX-TB study) of patients with extrapulmonary tuberculosis (EPTB). Adult patients newly diagnosed with EPTB will prospectively be enrolled into the study.
- Trial name
- mEX-TB (NCT06875336)
- Testing
- biomarker analysis
- Where
- 6 sites in Germany
- Volunteers
- 150 people
- Sponsor
- University of Cologne